Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis

Respiration

Volumn 90, Issue 4, 2015, Pages 299-305

  Orriols, Ramon ^a,b,c,e   Hernando, Rosana ^b,c,d   Ferrer, Adelaida ^b   Terradas, Sonia ^b   Montoro, Bruno ^b  

^a HOSPITAL JOSEP TRUETA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d PARC SANITARI SANT JOAN DE DÉU   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Eradication treatment; Nebulised tobramycin; Non cystic fibrosis bronchiectasis; Pseudomonas aeruginosa

Indexed keywords

CEFTAZIDIME; PLACEBO; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BRONCHIECTASIS; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MALE; NEBULIZATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SHORT COURSE THERAPY; TREATMENT DURATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; AGED; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; CEFTAZIDIME; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; TOBRAMYCIN;

EID: 84946500265     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000438490     Document Type: Article

References (39)

1. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100
2. Doring G, Flume P, Heijerman H, Elborn JS; Consensus Study Group: Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros 2012; 11: 461-479
3. Langton Hewer SC, Smith AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009; 4: CD004197
4. Wells A, Desai S, Whetton C, Wilson R, Cole P. The isolation of Pseudomonas aeruginosa from sputum in idiopathic bronchiectasis: an association with extensive disease and severe airflow obstruction. Am Rev Respir Dis 1993; 147: A645
5. Wilson CB, Jones PW, OLeary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10: 1754-1760
6. Caballero E, Drobnic ME, Perez MT, Manresa JM, Ferrer A, Orriols R. Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis. Thorax 2001; 56: 669-674
7. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9: 1601-1604
8. Orriols R, Roig J, Ferrer J, Sampol G, Rosell A, Ferrer A, Vallano A. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa . Respir Med 1999; 93: 476-480
9. Drobnic ME, Sune P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 2005; 39: 39-44
10. Haworth cS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014; 189: 975-982
11. Barker AF, Couch L, Fiel SB, Gotfried MH, Illowhite J, Meyer KC, ODonnell A, Sahn SA, Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen JV, Well CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485
12. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, Greening AP, Haslett C, Hill AT. A randomized controlled trial of nebulized gentamicin in noncystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499
13. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65(suppl 1): i1-i58
14. Quon BS, Goss HC, Ramsey BW. Inhaled antibiotics for lower airways infections. Ann Am Thorac Soc 2014; 11: 425-434
15. Vendrell M, Munoz G, De Gracia J. Evidence of inhaled tobramycin in non-cystic fibrosis bronchiectasis. Open Respir Med J 2015; 9: 30-36
16. Casals T, Nunes V, Palacio A, Gimenez J, Gaona A, Ibanez N, Morral N, Estivill X. Cystic fibrosis in Spain: high frequency of mutation G542X in the Mediterranean coastal area. Hum Genet 1993; 91: 66-70
17. Westerman EM, Boer AH, Touw DJ, Brun PP, Roldaan AC, Frijlink HW, Heijerman HG. Aerosolization of tobramycin (TOBI) with the PARI LC PLUS reusable nebulizer: which compressor to use?. Comparison of the CR60 to the PortaNeb compressor. J Aerosol Med Pulm Drug Deliv 2008; 21: 269-280
18. Nebulizer therapy. Guidelines. British Thoracic Society Nebulizer Project Group. Thorax 1997; 52(suppl 2): S4-S24
19. Murphy TF, Sethi S. Bacterial infection in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146: 1067-1083
20. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorates sputum. Mayo Clin Proc 1975; 50: 339-344
21. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 1996; 45: 493-496
22. Gardner RM, Hankinson JL. Standardization of spirometry -1987 ATS update (American Thoracic Society). J Occup Med 1988; 30: 272-273
23. Moore RD, Smith cR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis 1984; 149: 23-30
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. Georges Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327
25. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642
26. ODonnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998; 113: 1329-1334
27. Levy J. Antibiotic activity in sputum. J Pediatr 1986; 108(5 pt 2): 841-846
28. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, Grimwood K. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001; 138: 699-704
29. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012; 106: 356-360
30. Valerius NH, Koch c, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in chronic fibrosis by early treatment. Lancet 1991; 338: 725-726
31. Wiesemann HG, Steinkamp G, Ratjen F, Bauernfeind A, Przyklenk B, Doring G, von Der Hardt H. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25: 88-92
32. Ratjen F, Doring G, Nikolaizik WH. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 2001; 358: 983-984
33. Ratjen F, Munck A, Kho P, Angyalosi G; ELITE Study Group: Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65: 286-291
34. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators: Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165: 847-856
35. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B; Cystic Fibrosis Therapeutics Development Network Study Group: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-849
36. Doring G, Hoiby N. Longitudinal study of immune response to Pseudomonas aeruginosa antigens in cystic fibrosis. Infect Immun 1983; 42: 197-201
37. Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Doring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B. Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial. J Cyst Fibros 2013; 12: 147-153
38. Baumann U, Stoklossa C, Greiner W, von Der Schulenburg JM, von Der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros 2003; 2: 84-90
39. Frederiksen B, Koch c, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23: 330-335